Analytical Data
-
Gene name
MAGEC2
- Application
-
Alternative Names
(Cancer/testis antigen 10)(CT10)(Hepatocellular carcinoma-associated antigen 587)(MAGE-C2 antigen)(MAGE-E1 antigen)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UBF1
-
Expression Region
1-373aa
-
Molecular Weight
46.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEC2, part of the MAGE (Melanoma Antigen Gene) family, is a gene that encodes a member of the cancer/testis (CT) antigen family, which is primarily expressed in male germ cells and various malignancies, including melanoma, breast, and lung cancers. The aberrant expression of MAGEC2 in tumors has made it a subject of great interest in cancer immunotherapy research, particularly for developing targeted therapies and vaccines. Its restricted expression profile offers a promising strategy for cancer treatment, as therapies targeting MAGEC2 could potentially minimize off-target effects and enhance the immune response against tumor cells. Recent studies have focused on the structural characterization and functional analysis of the MAGEC2 recombinant protein, elucidating its role in tumor immunogenicity and its interaction with major histocompatibility complex (MHC) molecules. Understanding the mechanisms by which MAGEC2 contributes to tumor immune evasion is crucial for the design of effective immunotherapeutic approaches. In addition, research on MAGEC2 has expanded to explore its potential as a biomarker for cancer diagnosis and prognosis, making it a vital area of investigation in the quest for more effective cancer treatment options. As the understanding of the MAGEC2 protein continues to evolve, it holds the potential to significantly impact cancer therapy by informing the development of novel therapeutic strategies aimed at harnessing the immune system to target and eliminate cancer cells.
